T
TOBAM Portfolio holdings
AUM
$256M
This Quarter Return
+10.73%
1 Year Return
+13.59%
3 Year Return
+36.98%
5 Year Return
+80%
10 Year Return
+220.89%
AUM
$1.12B
AUM Growth
+$1.12B
(-2.4%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-11.94%
Top 10 Holdings %
Top 10 Hldgs %
27.63%
Holding
403
New
29
Increased
122
Reduced
176
Closed
26
Top Buys
| 1 |
Progressive
PGR
|
$11.2M |
| 2 |
Archer Daniels Midland
ADM
|
$8.54M |
| 3 |
Humana
HUM
|
$8.26M |
| 4 |
Toro Company
TTC
|
$7.73M |
| 5 |
Nutanix
NTNX
|
$7.41M |
Top Sells
| 1 |
Super Micro Computer
SMCI
|
$33.7M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$15.2M |
| 3 |
Merck
MRK
|
$13.1M |
| 4 |
Eli Lilly
LLY
|
$10.3M |
| 5 |
Las Vegas Sands
LVS
|
$9.48M |
Sector Composition
| 1 | Healthcare | 32.63% |
| 2 | Consumer Staples | 23.65% |
| 3 | Financials | 11.73% |
| 4 | Technology | 9.93% |
| 5 | Communication Services | 8.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $33.9M | 3.04% |
43,604
-13,302
| -23% | -$10.3M |
|
2
General Mills
GIS
$26.4B
| $32.9M | 2.95% |
470,725
-24,876
| -5% | -$1.74M |
|
3
AbbVie
ABBV
$372B
| $31.9M | 2.86% |
175,361
-43,386
| -20% | -$7.9M |
|
4
Church & Dwight Co
CHD
$22.7B
| $30.9M | 2.77% |
296,417
-6,566
| -2% | -$685K |
|
5
McKesson
MCK
$85.4B
| $30.6M | 2.75% |
57,063
-5,261
| -8% | -$2.82M |
|
|
6
Progressive
PGR
$145B
| $30M | 2.69% |
145,248
+54,354
| +60% | +$11.2M |
|
7
Clorox
CLX
$14.5B
| $29.8M | 2.67% |
194,540
-26,793
| -12% | -$4.1M |
|
8
Cboe Global Markets
CBOE
$24.7B
| $29.6M | 2.65% |
161,122
+39,540
| +33% | +$7.26M |
|
|
9
Humana
HUM
$36.5B
| $29.5M | 2.64% |
84,942
+23,819
| +39% | +$8.26M |
|
10
AT&T
T
$209B
| $29.1M | 2.61% |
1,653,323
-45,999
| -3% | -$810K |
|
11
J.M. Smucker
SJM
$11.8B
| $28.2M | 2.53% |
224,000
-24,636
| -10% | -$3.1M |
|
|
12
Merck
MRK
$210B
| $27.5M | 2.46% |
208,346
-99,582
| -32% | -$13.1M |
|
13
Kroger
KR
$44.9B
| $27.5M | 2.46% |
480,565
-94,848
| -16% | -$5.42M |
|
14
Newmont
NEM
$81.7B
| $25.9M | 2.32% |
721,794
+18,781
| +3% | +$673K |
|
15
Pfizer
PFE
$141B
| $25.2M | 2.26% |
908,042
+18,715
| +2% | +$519K |
|
16
Kellanova
K
$27.6B
| $25.1M | 2.25% |
437,482
-144,240
| -25% | -$8.26M |
|
17
United Therapeutics
UTHR
$13.8B
| $25M | 2.24% |
108,647
-5,110
| -4% | -$1.17M |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $24.6M | 2.2% |
178,253
-48,588
| -21% | -$6.7M |
|
19
Johnson & Johnson
JNJ
$427B
| $24.1M | 2.16% |
152,093
-53,495
| -26% | -$8.46M |
|
20
Verizon
VZ
$186B
| $22.9M | 2.05% |
545,873
+7,920
| +1% | +$332K |
|
21
Schlumberger
SLB
$55B
| $21.1M | 1.89% |
384,288
-16,993
| -4% | -$931K |
|
22
Arista Networks
ANET
$172B
| $20.8M | 1.86% |
71,664
-16,619
| -19% | -$4.82M |
|
23
Campbell Soup
CPB
$9.52B
| $20.2M | 1.81% |
454,302
-82,788
| -15% | -$3.68M |
|
24
Bristol-Myers Squibb
BMY
$96B
| $19.6M | 1.76% |
361,720
-170,184
| -32% | -$9.23M |
|
25
DaVita
DVA
$9.85B
| $16.1M | 1.44% |
116,735
-19,488
| -14% | -$2.69M |
|